Elsevier

Biochemical Pharmacology

Volume 47, Issue 10, 18 May 1994, Pages 1805-1812
Biochemical Pharmacology

11β-hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds

https://doi.org/10.1016/0006-2952(94)90309-3Get rights and content

Abstract

The enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD) is considered to confer mineralocorticoid specificity on the non-selective Type I adrenocorticoid receptor by converting active 11-hydroxyglucocorticoids to receptor-inactive 11-oxo metabolites, in mineralocorticoid target tissues like the kidney. However, 11β-HSD is also present in the liver, where it may regulate steroid exposure to the glucocorticoid Type II receptor. Because of the much higher activities compared to that in kidney, liver 11β-HSD possibly has additional functions besides the metabolism of glucocorticoids. In the present investigation we have isolated 11β-HSD from mouse liver microsomes and demonstrate that the homogeneously purified enzyme is also capable of catalyzing the reductive metabolism of xenobiotic carbonyl compounds such as metyrapone, p-nitroacetophenone and p-nitrobenzaldehyde. Enzyme kinetic studies revealed that, in addition to NADP+, mouse liver 11β-HSD also accepts NAD+ as cosubstrate for glucocorticoid 11β-dehydrogenation. NADH as cosubstrate for 11-oxoreduction plays only a minor role compared to that with NADPH, a fact which is also true for xenobiotic carbonyl reduction. Inhibition experiments revealed strong sensitivity of xenobiotic carbonyl reduction to glucocorticoids. The competitive nature of this inhibition suggests that both glucocorticoids and xenobiotic carbonyl substances bind to the same catalytically active site of 11β-HSD. High enzyme activities were also found in microsomal fractions of the ovary and adrenal gland but, although expressing considerable glucocorticoid 11-dehydrogenation activity (one third that of liver), almost no carbonyl reduction was detectable in kidney microsomes. Immunoblot analysis with polyclonal antibodies directed against the liver 11β-HSD did not yield an immunological crossreaction in the same tissues. In conclusion, corresponding to the cytosolic aldo-keto reductases, microsomal 11β-HSD of liver may be considered to play a role in the phase I biotransformation of pharmacologically relevant carbonyl substances as well as protecting organisms against toxic carbonyl compounds by converting them to less lipophilic and more soluble and conjugatable metabolites. Discrepancies in bioactivity together with the lack of response to anti-liver 11β-HSD antibodies strongly indicate the existence of distinct forms of 11β-HSD to be present in kidney, adrenal gland and ovary. The ability of xenobiotic carbonyl reduction might be another distinguishing feature among the various 11β-HSD isozymes.

References (38)

  • UC Oppermann et al.

    Homologies between enzymes involved in steroid and xenobiotic carbonyl reduction in vertebrates, invertebrates and proearyonts

    J Steroid Biochem Mol Biol

    (1992)
  • C Monder et al.

    Corticosteroid 11 beta-hydroxysteroid dehydrogenase activities in vertebrate liver

    Steroids

    (1988)
  • H Sawada et al.

    Mouse liver dihydrodiol dehydrogenases. Identity of the predominant and a minor form with 17 beta-hydroxysteroid dehydrogenase and aldehyde reductase

    Biochem Pharmacol

    (1988)
  • R Pietruszko et al.

    Aldehyde reductase from rat liver is a 3 α-hydroxysteroid dehydrogenase

    Biochem Pharmacol

    (1976)
  • JW Funder et al.

    Mineralocorticoid action: target specificity is enzyme, not receptor mediated

    Science

    (1988)
  • PM Stewart et al.

    Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle

    J Clin Invest

    (1988)
  • S Ulick et al.

    A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol

    J Clin Endocr Metab

    (1979)
  • IE Bush et al.

    Metabolism of 11-oxygenated steroids

    Biochem J

    (1968)
  • DR Keorner

    Assay and substrate specificity of liver 11β-hydroxysteroid dehydrogenase

    Biochim Biophys Acta

    (1969)
  • Cited by (90)

    • 11β-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story

      2015, Journal of Steroid Biochemistry and Molecular Biology
      Citation Excerpt :

      This reaction was dependent on NADPH and inhibited by dihydrotestosterone. Later, the enzyme involved was confirmed to be 11β-HSD1 and other substrates such as p-nitroacetophenone and p-nitrobenzaldehyde were described [90,91]. Further studies identified additional non-steroidal compounds as substrates of 11β-HSD1, namely ketoprofen, DFU-lactol, the anti-cancer drug candidate oracin, the tobacco constituent nicotine-derived nitrosamineketone (NNK) and the fungicide triadimefon ([92–98], for a more comprehensive review see also [46]).

    View all citing articles on Scopus
    View full text